MedTrace Logo

Effects of Neuromuscular Electrical Stimulation Combined With Ultrasound on Stroke Patients With Sarcopenia

NCT07708597 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 152

Last updated 2026-07-16

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if combining neuromuscular electrical stimulation (NMES) with therapeutic ultrasound (UT) can improve muscle mass, muscle strength, and physical function in stroke patients with sarcopenia.

The main questions it aims to answer are:

Does combined NMES and UT therapy increase muscle mass and strength more than conventional rehabilitation alone?

Does the combined therapy improve physical function (balance, gait, and activities of daily living) better than either therapy alone?

Researchers will compare four groups:

Conventional rehabilitation only (control group)

Conventional rehabilitation plus UT

Conventional rehabilitation plus NMES

Conventional rehabilitation plus combined UT and NMES

Participants will:

Receive 4 weeks of rehabilitation therapy, 6 days per week

Undergo assessments of muscle mass (via ultrasound), muscle strength (handgrip, isokinetic testing), and physical function (Fugl-Meyer, FIM, balance, and gait tests) before and after the 4-week intervention

Receive either UT (1 MHz, 0.5-0.8 W/cm², 20 min/session, 2 sessions/day), NMES (50 Hz, 300μs pulse width, 20 min/session, 2 sessions/day), both, or standard care only

Conditions

Interventions

DEVICE

Therapeutic Ultrasound

Ultrasound therapy delivered at 1 MHz, 0.5-0.8 W/cm², 20 minutes per session, 2 sessions per day, 6 days per week for 4 weeks, using the PHYSIOSON-EXPERT device. Applied to the affected wrist extensors and quadriceps.

DEVICE

Neuromuscular Electrical Stimulation

Neuromuscular electrical stimulation delivered at 50 Hz, 300μs pulse width, intensity adjusted to visible muscle contraction, 20 minutes per session, 2 sessions per day, 6 days per week for 4 weeks, using the LGT-2320D device. Applied to the affected wrist extensors and quadriceps.

Sponsors & Collaborators

  • Nanjing First Hospital, Nanjing Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-01
Primary Completion
2025-11-01
Completion
2026-07-15

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07708597 on ClinicalTrials.gov